Changes of RAPD profile of Trypanosoma cruzi II with Canova and Benznidazole

Denise Lessa Aleixo; Fabiana Nabarro Ferraz; Carolina Sundin de Melo; Mônica Lúcia Gomes; Max Jean Toledo; Edílson Noboyoshi Kaneshima; Ciomar Aparecida Bersani-Amado; Silvana Marques Araújo

doi:10.1016/j.homp.2008.02.003

Homeopathy, Inhaltsverzeichnis

Homeopathy 2008; 97(02): 59-64
DOI: 10.1016/j.homp.2008.02.003

Original Paper

Changes of RAPD profile of Trypanosoma cruzi II with Canova and Benznidazole

Autoren

Denise Lessa Aleixo

¹Universidade Estadual de Maringá, Maringá, Paraná, Brazil
Fabiana Nabarro Ferraz

²Parasitologia Básica, Universidade Estadual de Maringá, Maringá, Paraná, Brazil
Carolina Sundin de Melo

²Parasitologia Básica, Universidade Estadual de Maringá, Maringá, Paraná, Brazil
Mônica Lúcia Gomes

²Parasitologia Básica, Universidade Estadual de Maringá, Maringá, Paraná, Brazil
Max Jean Toledo

²Parasitologia Básica, Universidade Estadual de Maringá, Maringá, Paraná, Brazil
Edílson Noboyoshi Kaneshima

³Departamento de Análises Clínicas, Universidade Estadual de Maringá, Maringá, Paraná, Brazil
Ciomar Aparecida Bersani-Amado

⁴Departamento de Farmácia e Farmacologia, Universidade Estadual de Maringá, Maringá, Paraná, Brazil
Silvana Marques Araújo

²Parasitologia Básica, Universidade Estadual de Maringá, Maringá, Paraná, Brazil

Verantwortlicher Herausgeber dieser Rubrik:

Abstract

Chagas disease, caused by the protozoan Trypanosoma cruzi, involves immunomediated processes. Canova (CA) is a homeopathic treatment indicated in the diseases in which the immune system is depressed. This study evaluated the Random Amplification of Polymorphic DNA (RAPD) profile of T. cruzi under the influence of CA and Benznidazole (BZ). Mice infected with the genetic lineage of T. cruzi II (Y strain) were divided into 4 groups:

Infected animals treated with saline solution (control group); treated with CA; treated with BZ; treated with CA and BZ combined.

Treatment was given at the 5th–25th days of infection (D5–25). The parasites were isolated by haemoculture in Liver Infusion Tryptose (LIT) medium: at D5 (before treatment), D13, 15 and 25 (during treatment) and D55 and 295 (after treatment). DNA was extracted from the mass of parasites. RAPD was done with the primers λgt11-F, M13F-40 and L15996, the amplified products were eletrophoresed through a 4% polyacrylamide gel. Data were analyzed by the coefficient of similarity using the DNA-POP program.

163 markers were identified, 5 of them monomorphic. CA did not act against the parasites when used alone. The RAPD profiles of parasites treated with BZ and CA + BZ were different from those in the control group and in the group treated with CA. The actions of the CA and BZ were different and the action of BZ was different from the action of CA + BZ. These data suggest that CA may interact with BZ. The differences in the RAPD profile of the Y strain of T. cruzi produced by BZ, CA + BZ and the natural course of the infection suggest selection/suppression of populations.

Keywords

Trypanosoma cruzi - T. cruzi II - RAPD - Canova medication - Benznidazole - Homeopathy

Volltext

Referenzen

References
1 Moncayo A. Chagas disease: current epidemiological trends after the interruption of vetorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 2003; 98 (05) 577-591.
2 OPS (Organización Panamericana de la Salud). XIII Reunion de la comisión Intergubernamental para la eliminación de Triatoma infestans y la interrupción de la tripanosomiasis Americana por transfusion. 2004, pp 29–31.
3 Suasnáber D., Arias E., Streiger M. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop São Paulo 2000; 42: 99-109.
4 Laguens R.P., Cabeza Meckert P.M., Vigliano C.A. Pathogenesis of human chronic chagasic myocarditis. Medicina (B Aires) 1999; 59 (02) 63-68.
5 Higuchi M.L., Gutierrez P.S., Aiello V.D. Immunohistochemical characterization of infiltrating cells in human chronic chagasic myocarditis: comparison with myocardial rejection process. Virchows Arch A Pathol Anat Histol 1993; 423: 157-160.
6 Reyes P.A., Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev 2005 (04) [Art. No.: CD004102].
7 Fabbro D.L., Streiger M.L., Arias E.D., Bizai M.L., Del Barco M., Amicone N.A. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007; Jan–Feb; 40 (01) 1-10.
8 Toledo M.J.O., Bahia M.T., Veloso V.M. et al. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes. J Antim Chemot 2004; 53 (06) 1045-1053.
9 Pupulin ART, Neto IR, Gabriel M. Avaliação dos efeitos do medicamento Canova sobre a infecção experimental de camundongos pelo Trypanosoma cruzi. In: Anais da XX Reunião Anual de Pesquisa Aplicada em doença de Chagas e VIII Reunião Anual de Pesquisa Aplicada de Leishmaniose, Uberaba, 2004.
10 Ribeiro Filho A. Repertório de Homeopatia Ed Organon, 1a Edição, p 1900.
11 Pereira W.K.V., Lonardoni M.V.C., Grespan R., Caparroz-Assef S.M., Cuman R.K.N., Bersani-Amado C.A. Immunomodulatory effect of Canova medication on experimental Leishmania amazonensis infection. J Infect 2005; 51: 157-164.
12 Sasaki M.G.M., Mariano F.C., Gurgel L.P., Probst S. Estudo clínico randomizado placebo controlado para avaliar a eficácia e segurança do Método Canova na terapêutica de pacientes portadores de HIV/Aids em uso de anti-retrovirais. Braz J Infect Dis 2001; 5 (01) 58.
13 Seligmann I.C., Lima P.D.L., Cardoso P.C.S. et al. The anticancer homeophathic composite “Canova Method” is not genotoxic for human lymphocytes in vitro . Genet Mol Res 2003; 2 (02) 223-228.
14 Piemonte M.R., Buchi D.F. Analysis of IL-2, IFN-γ and TNF-α production, α5β1 integrins and actin filaments distribution in peritoneal mouse macrophages treated with homeopathic medicament. J Submicrosc Cytol Pathol 2002; 34 (03) 255-263.
15 Bellavite P., Ortolani R., Pontarollo F., Piasere V., Benato G., Conforti A. Immunology and homeopathy. Clinical studies – part 1 . eCAM 2006: 1-9.
16 Brisse S., Verhoef J., Tibayrenc M. Characterisation of large and small subunit rRNA and mini-exon genes further supports the distinction of six Trypanosoma cruzi lineages. Int J Parasitol 2001; 31 (11) 1218-1226.
17 Walsh J., McClelland M. Genomic fingerprinting using arbitrary primed PCR and a matrix of pairwise combination of primers. Nucleic Acids Res 1990; 18: 7213-7218.
18 Willians J., Kubelik A.R., Livak K.J. DNA polymorphisms amplified by arbitrary primers are useful as genetic markers. Nucleic Acids Res 1990; 18: 6531-6535.
19 Pereira da Silva L.H., Nussensweig V. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin Biol (Sao Paulo) 1953; 20 (30) 191-208.
20 Araújo S.M., Chiari E. Caracterização biológica de clones das cepas Y, CL e MR de Trypanosoma cruzi em camundongos C3H isogênicos. Mem Inst Oswaldo Cruz 1988; 83: 175-181.
21 Macedo A.M., Martins M.S., Chiari E., Pena S.D.J. DNA fingerprinting of Trypanosoma cruzi: a new tool for characterization of strains and clones. Mol Biochem Parasitol 1992; 55: 147-154.
22 Gomes M.L., Macedo A.M., Pena S.D.J., Chiari E. Genetic relationship between Trypanosoma cruzi strains isolated from chronic chagasic patients in southern Brazil as revealed by RAPD and SSR-PCR analysis. Acta Trop 1998; 69: 99-109.
23 D`Ávila D.A., Gontijo E.D., Lages-Silva E., Meira W.S.F., Chiari E., Galvão L.M.C. Random amplified polymorphic DNA profiles of Trypanosoma cruzi isolates from chagasic patients with different clinical forms. Parasitol Res 2006; 98: 455-461.
24 Godoy L.C., Cardozo R.M., Moraes G.V. Avaliação de diversidade genética em subspécies e cruzamento de avestruzes (Struthio camelus) com o uso de maracadores RAPD. Acta Sci 2005; 27 (02) 199-206.
25 Pupulin ART, Araújo SM, Bersani-Amado CAB. Efeito do medicamento Canova sobre o nível de TNF-alfa no plasma de camundongos infectados pelo Trypanosoma cruzi. In: Anais da XXI Reunião Anual de Pesquisa Aplicada em Doença de Chagas e Leishmaniose: XXI Reunião Anual de Pesquisa Aplicada em Doença de Chagas e Leishmaniose, Uberaba, 2005.
26 Murta S.M.F., Ropert C., Alves R.O., Gazzinelli R.T., Romanha A.J. In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant Trypanosoma cruzi population. Parasite Immunol 1999; 21 (10) 535-544.
27 Romanha A.J., Alves R.O., Murta S.M., Silva J.S., Ropert C., Gazzinelli R.T. Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. J Infect Dis 2002; 186 (06) 823-828.
28 Lopes L., Godoy L.M.F., Oliveira C.C., Gabardo J., Schadeck R.J.G., Buchi D.F. Phagocytosis, endosomal/lysosomal system and other cellular aspects of macrophage activation by Canova medication. Micron 2006; 37: 277-287.
29 Oliveira C.C., Oliveira S.M., Godoy L.M.F., Gabardo J., Buchi D.F. Canova, a Brazilian medical formulation, alters oxidative metabolism of mice macrophages. J Infect 2006; 52: 420-432.